Compare · RMD vs STVN
RMD vs STVN
Side-by-side comparison of ResMed Inc. (RMD) and Stevanato Group S.p.A. (STVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and STVN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.33B, about 4.8x STVN ($5.96B).
- Over the past year, RMD is down 28.6% and STVN is down 23.4% - STVN leads by 5.2 points.
- RMD has been more active in the news (7 items in the past 4 weeks vs 1 for STVN).
- RMD has more recent analyst coverage (25 ratings vs 22 for STVN).
- Company
- ResMed Inc.
- Stevanato Group S.p.A.
- Price
- $195.32+1.83%
- $19.76+1.78%
- Market cap
- $28.33B
- $5.96B
- 1M return
- -0.61%
- +14.75%
- 1Y return
- -28.59%
- -23.40%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 7
- 1
- Recent ratings
- 25
- 22
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.
Latest RMD
- BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)
- ResMed downgraded by RBC Capital Mkts with a new price target
- ResMed downgraded by Citigroup with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Resmed Announces Agreement to Sell MatrixCare Business
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
- ResMed downgraded by Morgan Stanley with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)
Latest STVN
- Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
- Director Balachandran Madhavan was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 5% to 69,458 units (SEC Form 4) to satisfy withholding obligation
- Chief Financial Officer Dal Lago Marco was granted 2,356 units of Ordinary Shares and converted options into 7,997 units of Ordinary Shares, increasing direct ownership by 14% to 85,353 units (SEC Form 4)
- Director Lin Sue-Jean was granted 4,975 units of Ordinary Shares, increasing direct ownership by 249% to 6,975 units (SEC Form 4)
- Director Morel Donald E Jr was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 10% to 37,424 units (SEC Form 4) (tax withholding)
- Director Santel Luciano was granted 4,975 units of Ordinary Shares, increasing direct ownership by 278% to 6,762 units (SEC Form 4)
- Director Magistretti Elisabetta was granted 4,975 units of Ordinary Shares (SEC Form 4)
- Officer Stocchi Mauro was granted 2,101 units of Ordinary Shares and converted options into 6,586 units of Ordinary Shares, increasing direct ownership by 2% to 413,629 units (SEC Form 4)
- Director Flynn Karen was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 153% to 5,757 units (SEC Form 4) (tax withholding)
- Director Federici William J was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 15% to 26,991 units (SEC Form 4) to satisfy withholding obligation